Rosetta Genomics' Q3 Loss Rises 13 Percent

The firm reported no revenues for the quarter, but it anticipates revenues of between $2 million and $4 million in 2010 tied to sales of its microRNA-based tests.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.